Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure
Paul Palumbo(Dartmouth College), Avy Violari(University of the Witwatersrand), Jane C. Lindsey(Harvard University Press), Patrick Jean‐Philippe(Jackson Foundation), Raziya Bobat(Jacobi Medical Center), Portia Kamthunzi, Elizabeth Petzold(Duke Medical Center), Linda Millar(Frontier Science & Technology Research Foundation, Inc.), Philippa Musoke(Centers for Disease Control and Prevention), Elaine J. Abrams(ICAP Global Health), Mutsa Bwakura‐Dangarembizi(National Institutes of Health), Susan H. Eshleman(Johns Hopkins University), Lynette Purdue(National Institutes of Health), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Michael D. Hughes(Virginia Tech), Werner Schimana(National Institute of Allergy and Infectious Diseases), Tammy Meyers(University of the Witwatersrand), Mark F. Cotton(Stellenbosch University)
Cited by 220
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896